

Discussions with leaders: Herrmann and Czernin talk with Diane Simeone, MD, about her career achievements in advancing clinical research in pancreatic cancer. **Page 185**

Trustworthy AI ecosystems: Saboury and members of an SNMMI task force outline opportunities and challenges in creating strategic plans for establishment of trustworthy artificial intelligence ecosystems in nuclear medicine. **Page 188**

WB PET and whole-person research: Sundar and colleagues present a forward-looking assessment of the possibilities offered by total-body PET for investigating and illuminating multiorgan systemic interactions. **Page 197**

Scientific integrity in nuclear medicine: Kwee and colleagues report on the results of an international survey of nuclear medicine scientists' experience with scientific fraud, publication bias, and honorary authorship. **Page 200**

SSTR procedure standard: Hope and colleagues detail consensus procedure guidelines intended to assist physicians in recommending, performing, interpreting, and reporting the results of somatostatin-receptor PET imaging in patients with neuroendocrine tumors. **Page 204**

²²⁵Ac-DOTATATE TAT in GEP NETs: Ballal and colleagues evaluate long-term outcomes of targeted α -therapy with ²²⁵Ac-DOTATATE in patients with somatostatin receptor-expressing advanced-stage metastatic gastroenteropancreatic neuroendocrine tumors. **Page 211**

Assessing ²²⁵Ac-TAT studies: Strosberg and colleagues offer perspective on results and analysis of a study in this issue of *JNM* reporting on real-world experience using targeted α -therapy in neuroendocrine tumor patients by radiolabeling DOTATATE with ²²⁵Ac. **Page 219**

SPECT as ¹⁷⁷Lu-PSMA-617 response biomarker: Pathmanandavel and colleagues investigate the predictive value of serial ¹⁷⁷Lu-PSMA SPECT imaging in monitoring treatment response to ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer. **Page 221**

Eligibility for ¹⁷⁷Lu-PSMA-617 therapy in mCRPC: Cook and colleagues compare lesion and lesion-to-normal-organ ratios between ⁶⁸Ga-PSMA-11 PET/CT and ^{99m}Tc-MIP-1404 SPECT/CT

to evaluate eligibility for ¹⁷⁷Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer. **Page 227**

Cyclotron-produced ⁶⁸Ga tracer: Tremblay and colleagues report on a comparison of DOTATATE labeling with ⁶⁸Ga produced by a cyclotron or eluted from a generator to demonstrate safety and diagnostic efficacy of the cyclotron-produced radiopharmaceutical as a routine diagnostic tool. **Page 232**

PRoLoG initiative on Lugano classification: Ricard and colleagues present the second in a 2-part series on consensus recommendations from academic and industry experts in lymphoma and imaging for consistent application of the Lugano lymphoma classification system. **Page 239**

⁶⁸Ga-FAPI PET/CT for IPMN: Lang and colleagues describe the clinical feasibility of accurate additional identification of intraductal papillary mucinous neoplasms by ⁶⁸Ga-FAPI PET/CT in patients with MRI- or CT-proven cystic pancreatic lesions. **Page 244**

Integrin $\alpha_v\beta_3$ PET in NENs: Carlsen and colleagues use ⁶⁸Ga-NODAGA-E[c(RGDyK)]₂ for PET/CT imaging of integrin $\alpha_v\beta_3$ in patients with neuroendocrine neoplasms and explore its potential utility in disease prognosis. **Page 252**

SPECT MBF and MFR variability: Bailly and colleagues study intra- and interuser reproducibility of myocardial blood flow and myocardial flow reserve measurements in patients referred for dynamic cadmium zinc telluride-based pinhole cardiac SPECT. **Page 260**

Early-phase amyloid PET and ¹⁸F-FDG PET: Boccalini and colleagues compare early-phase amyloid PET and ¹⁸F-FDG PET imaging at the individual level and report on their relative abilities to identify typical neurodegenerative patterns. **Page 266**

LB copathology and PET in AD: Silva-Rodríguez and colleagues analyze relationships between neuropathologically assessed tau pathology, Lewy body pathology, substantia nigra neuronal loss, and antemortem ¹⁸F-FDG PET hypometabolism in patients with clinical Alzheimer disease presentation. **Page 274**

Relative cerebral blood flow effects: Visser and colleagues compare semiquantitative and

quantitative parameters of longitudinal ¹⁸F-flortaucipir PET scans in individuals with subjective cognitive decline or Alzheimer disease and explore the effects of changes in blood flow on these metrics. **Page 281**

Skull binding in tau and amyloid PET: Flores and colleagues characterize the frequency of off-target [¹⁸F]flortaucipir skull binding on PET, its influence on estimates of Alzheimer disease pathology, and whether skull uptake is a stable feature across time and tracers. **Page 287**

RSNA QIBA profile for amyloid PET: Smith and members of the Quantitative Imaging Biomarkers Alliance detail development and validation of a profile to characterize and reduce the variability of SUVrs in amyloid PET imaging, increasing statistical power and utility. **Page 294**

Machine learning in PET/MRI: Morawitz and colleagues investigate whether machine learning prediction models based on simple assessable MRI or PET/MRI features can determine nodal status in newly diagnosed breast cancer for decision support in axillary lymph node staging. **Page 304**

Fetal dose in PET/CT: Burton and colleagues provide radiation dose estimates to the fetus from PET/CT with protocols that are adapted to University of Michigan low-dose protocols for patients known to be pregnant. **Page 312**

⁶⁴Cu-LLP2A in MM: Laforest and colleagues report on preclinical and first-in-humans studies of safety and efficacy with this very late antigen 4-targeting radiopharmaceutical with promise for managing patients with multiple myeloma. **Page 320**

⁹⁰Y-FAPI PET quantification: Kersting and colleagues explore the conditions needed for reliable lesion image quantification in ⁹⁰Y-FAPI radionuclide therapy using a digital PET/CT system. **Page 329**

GD2 PET/MRI in sarcoma: Trautwein and colleagues present details on clinical [⁶⁴Cu]Cu-DOTAGA-ch14.18/CHO PET/MRI to evaluate expression of the disialoganglioside GD2 in an osteosarcoma patient with pulmonary metastasis. **Page 337**